Mereo BioPharma Group/$MREO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Mereo BioPharma Group
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Ticker
$MREO
Sector
Primary listing
Employees
39
Headquarters
Website
MREO Metrics
BasicAdvanced
$50m
-
-$0.22
-
-
Price and volume
Market cap
$50m
52-week high
$3.05
52-week low
$0.20
Average daily volume
5.1m
Financial strength
Current ratio
6.481
Quick ratio
6.117
Interest coverage (TTM)
-381.17%
Profitability
EBITDA (TTM)
-35.578
Gross margin (TTM)
73.40%
Net profit margin (TTM)
-7,142.00%
Operating margin (TTM)
-7,242.20%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-41.55%
Return on equity (TTM)
-75.87%
Valuation
Price to revenue (TTM)
100.417
Price to book
1.47
Price to tangible book (TTM)
1.48
Growth
Earnings per share change (TTM)
-28.18%
3-year earnings per share growth (CAGR)
-14.34%
What the Analysts think about MREO
Analyst ratings (Buy, Hold, Sell) for Mereo BioPharma Group stock.
MREO Financial Performance
Revenues and expenses
MREO Earnings Performance
Company profitability
MREO News
AllArticlesVideos
MREO DEADLINE ALERT: ROSEN, A LEADING NATIONAL FIRM, Encourages Mereo BioPharma Group plc Investors to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
Newsfile Corp·2 months ago
MREO FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Mereo BioPharma (MREO) Investors of Securities Class Action Deadline on April 6, 2026
Business Wire·2 months ago
MREO DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Mereo BioPharma Group plc Investors with Losses in Excess of $100K to Secure Counsel Before Important April 6 Deadline in Securities Class Action - MREO
Newsfile Corp·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs